Trial Profile

Phase I Study of Docetaxel, Prednisone and Pazopanib in Men With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and Poor-Risk Factors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 21 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pazopanib (Primary) ; Docetaxel; Pegfilgrastim; Prednisone
Indications Prostate cancer
Focus Adverse reactions

Most Recent Events

03 Apr 2017 Status changed from active, no longer recruiting to completed.
03 Feb 2015 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
01 Apr 2014 The study phase was changed from I/II to phase I. Planned patient number was changed from 122 to 36 due to change in the treatment protocol according to the ClinicalTrials.gov record. Endpoints were modified according to ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com